An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
LENSAR, Inc. (Nasdaq: LNSR) granted two newly-hired non-executive employees stock options to purchase 875 shares of common stock. The options were granted as of May 1, 2024, with an exercise price of $3.07 per share. They vest over time based on continued service. The options are in line with Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2024 Employment Inducement Incentive Award Plan.
Positive
None.
Negative
None.
ORLANDO, Fla.--(BUSINESS WIRE)--
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock. The options were granted as of May 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $3.07 per share, which is equal to the closing price of the Company’s common stock on the grant date. The options vest as to 25% of the total amount of the award on the one-year anniversary of the grant date and in thirty-six substantially equal monthly installments thereafter, subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
When were the stock options granted to the newly-hired employees?
The stock options were granted as of May 1, 2024.
How many shares of the Company's common stock can be purchased with the options?
The options grant the right to purchase an aggregate of 875 shares of the Company's common stock.
What is the exercise price per share for the stock options?
The exercise price per share for the stock options is $3.07.
Under what conditions do the stock options vest?
The options vest as to 25% of the total amount on the one-year anniversary of the grant date, with the rest vesting in monthly installments thereafter based on continued service.
lensar® is the leader in next-generation femtosecond laser technology for refractive cataract surgery. the lensar laser system offers cataract surgeons precision and accuracy, while optimizing overall visual outcomes. the proprietary augmented reality™, lensar’s reconstructed 3-d imaging, measurement, and guidance system, provides high-resolution ocular images in a single scan. this technology facilitates precise surgical incisions and treatment for ultimate accuracy and reliable outcomes, all in a single procedure room. the lensar laser system is the only femtosecond cataract laser built specifically for refractive cataract surgery. because it was designed from the ground up, every aspect of the laser has been purposefully designed to meet the needs of cataract surgeons. lensar, inc. is committed to revolutionizing refractive eye surgery. our success depends on talented and motivated individuals who share our passion for making a difference in patients’ lives. we are a young and vibra
